2023-05-04 13:43:10 ET
Intellia Therapeutics ( NASDAQ: NTLA ) added ~13% on Thursday to reach the highest level in more than two months after the gene-editing company reported its Q1 2023 financials alongside updates from its clinical pipeline.
Notable disclosures include Intellia’s ( NTLA ) plans to submit a clinical trial application in mid-2023 to start a global pivotal study for its in-vivo gene editing candidate NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.
In 2021, Intellia ( NTLA ) and its partner for NTLA-2001 Regeneron ( REGN ) demonstrated the potential of in-vivo CRISPR genome editing for the first time in humans with Phase 1 data for the candidate in ATTR amyloidosis.
ATTR amyloidosis, a rare hereditary disorder, comes with polyneuropathy and cardiomyopathy manifestations, and the company’s trial targeted at the latter is expected to start by the year-end, subject to regulatory feedback.
As for financials, the company’s top line and bottom line beat Street forecasts while its cash, cash equivalents, and marketable securities stood at $1.2B at the end of the quarter compared to $1.3B at the end of 2022.
More on Intellia
- Intellia up 12% as Canaccord starts with Buy citing gene editing approach
- Intellia Therapeutics: Signs Of Possible Life
For further details see:
Intellia jumps 13% after Q1 updates